If approved, the Opdivo-based regimen would be the first immunotherapy-chemotherapy combination approved for this patient population in the EU
The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios
Tacrolimus is an immunosuppressant used in the treatment of organ transplant patients
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
For the treatment of stenotic lesions of arteriovenous fistula in the haemodialysis management of chronic renal failure
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
With just few days of treatment, the patient started responding well and finally complete clinical resolution of infection was attained
Acquisition of exclusive commercialization rights for European markets
The acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
Subscribe To Our Newsletter & Stay Updated
